Biotek-snakken — September 2022
-
Hele nyheden: European Medicines Agency’s CHMP adopts positive opinion for Ximluci
biosimilar candidate referencing Lucentis (ranibizumab). Positive opinion proposes authorization of Ximluci throughout EU. STADA CEO Peter Goldschmidt: “This positive opinion reflects STADA’s ongoing expansion of its biosimilars portfolio within Specialty Care, as well STADA Specialty Care’s https://xbrane.com/en/mfn_news/stada-and-xbrane-welcome-ema-positive-opinion-for-ranibizumab-biosimilar-candidate-ximluci -
Dejligt med STADA som trofast partner: In July 2018, STADA and Xbrane entered into an agreement under which the two companies are jointly responsible for development until regulatory approval and for manufacturing the finished product. STADA will hold the marketing authorizations and the commercial rights to the biosimilar across all territories included in the agreement, which covers Europe, the US, several countries in the Middle East and North Africa (MENA) region, and several Asia-Pacific (A
-
Enig Jazz….den skal holdes….ligger godt i mit langsigtede pensions depot….Tænker den vil klare sig godt i et recessions marked, så er helt tryg ved den, selvom udsvingene er lidt voldsomme indimellem
-
2 Biotech Stocks That Could Make You Richer https://www.proinvestor.com/investornyt/880059/2-biotech-stocks-that-could-make-you-richer
-
Ascelia Pharma - et nyt Veloxis eventyr? https://www.proinvestor.com/boards/106180
-
Biosimilarutvecklaren Xbrane Biopharmas partner kring Ximluci (ranibizumab) i Europa, Stada Arzneimittel, befinner sig i partnerskapsdiskussioner för utvalda marknader i Asien.
Det sade Bryan Kim, chef för specialistprodukter vid Stada Arzneimittel, under Xbrane Biopharmas kapitalmarknadsdag på torsdag.När Nyhetsbyrån Direkt ställde frågan om vilka asiatiska länder Bryan Kim ser som intressanta nämnde han Korea och Vietnam.
-
Enligt Xbrane Biopharmas styrelseordförande Anders Tullgren ska bolaget bli kassaflödespositiva i det fjärde kvartalet 2023 eller det första kvartalet 2024, vilket är ett upprepat mål.
-
-
Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study – ASCELIA
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announce ...
(www.ascelia.com)
-
Ascelia Pharma med gode data i andet support studie også
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind